StockData
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) stock

BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)

Close on Nov 17, 2026Market cap $10.88MP/E –Yield –

Bolt Biotherapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Bolt Biotherapeutics's price to book ratio was 1.0× on Nov 11, 2026, against 0.3× a year earlier. Over the last 5 years it ranged from 0.2× to 1.0×, with a median of 0.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.0×+0.6
2025Dec 31, 20250.3×+0.0
2024Dec 31, 20240.3×−0.0
2023Dec 29, 20230.3×+0.1
2022Dec 30, 20220.3×−0.4
2021Dec 31, 20210.7×–

More Bolt Biotherapeutics figures

See a number that looks wrong?